News & Updates
Filter by Specialty:
Show Multimedia Only

Esketamine monotherapy shows robust, rapid efficacy as treatment for TRD
17 Jul 2025
byMike Ng
Intranasal esketamine, administered at two fixed doses as monotherapy for treatment-resistant depression (TRD), has demonstrated robust and rapid efficacy in a phase IV double-blind, placebo-controlled randomized trial.
Esketamine monotherapy shows robust, rapid efficacy as treatment for TRD
17 Jul 2025
RA onset delayed through 4 years with 1-year abatacept treatment in at-risk individuals
16 Jul 2025
byMike Ng
A 12-month therapeutic intervention with self-administered abatacept can delay the onset of rheumatoid arthritis (RA) in at-risk individuals for up to 4 years, according to results from the ALTO follow-up study presented at EULAR 2025.